

# Supporting Information

Hsu and Mitragotri 10.1073/pnas.1016152108

## SI Materials and Methods

**Phage Display.** Phage library ( $2 \times 10^{11}$  pfu, 10  $\mu$ L) in 1 mL of PBS (pH 7.4) was placed in the donor compartment of the Franz diffusion cells (FDC). After 24 h, the liquid in the receiver compartment was removed and titered by adding an aliquot of the receiver solution to 200  $\mu$ L of *Escherichia coli* strain ER2738 (New England Biolabs) and plating on IPTG/Xgal plates. The number of blue plaques formed after incubation for 18 h at 37°C was counted and 20 plaques were randomly selected for sequencing. For subsequent screening rounds, 1 mL of the receiver solution was added to 20 mL of a 1:100 diluted overnight culture of ER2738 and grown for 4.5 h to amplify the phage. The phage were purified by PEG/NaCl precipitation and resuspended in PBS. The amplified phage were then used in the next round of screening. The number of phage placed in the donor compartment,  $2 \times 10^{11}$  pfu, was held constant for all 5 rounds of screening.

**Phage Permeation.** Permeability of various phage samples including phage with no peptide library, the entire phage library, skin penetrating and cell entering (SPACE)-peptide displaying phage and heptaglycine phage was determined following the same procedure described above (without the amplification and follow-up screening steps) using the number of phage colonies detected in the receiver samples and standard equations for determining permeability.

**Dermis Screen.** For the dermis screen, the phage display library was also placed in the donor compartment of the FDC. After 24 h, the liquid from the donor compartment was removed and the skin was placed at 60°C for 90 s. The epidermis was then removed from the dermis. To extract phage from the dermis, the dermis was cut up into small pieces and then homogenized (IKA disperser). The homogenate was spun down at 5,000 rpm for 5 min and then resuspended in PBS and incubated at room temperature for 5 min. The samples were then centrifuged again and washed two more times. After the final centrifuge spin, the homogenates were resuspended in 1% NP40 (Sigma) to elute the remaining phage from the dermis. The eluate was then plated and amplified according to the methods listed above. This cycle was repeated for a total of five rounds. At the end of the fifth round of screening, about  $1.9 \times 10^5$  phage were recovered from the dermis. Phage were sequenced and the three leading sequences in the fifth round were AC-KTGSNQ-CG (30%), AC-MGPSSML-CG (30%), and AC-TDPNQLQ-CG (20%).

**Phage Cloning.** Phage displaying specific sequences were cloned (M13KE vector, New England Biolabs). The peptide sequence was inserted in between the KpnI and EagI restriction sites. To differentiate the original M13KE vector from the modified M13KE vector containing the peptide insert, the reverse primer was engineered to modify the EagI restriction site (5'-CGGCCG-3') to the SacII restriction site (5'-CCGCGG-3') through two site mutations. Both the forward and reverse primers were used to replicate the entire vector. The forward primer was 5'-GTTCCGCGGAAACTGTTGAAAGTTGTTTAGCAAATCCC-3'. The reverse primer for TGSTQHQ and THGQTQS were 5'-TTTCCGCGGAACCTCCACCGCACTGATGCTGCTCGAACCCAGTACAAGCAGAGTGAGAATAGAAAGGTACTACTAAAGGAATTGCGAATAATAATTTTTTTCAC-3' and 5'-TTTCCGCGGAACCTCCACCGCA(AGACTGAGTCTGCCATG-

AGT)ACAAGCAGAGTGAGAATAGAAAGGTACTACTAAAGGAATTGCGAATAATAATTTTTTTCAC-3', respectively.

The replication products were purified and then digested with SacII to produce the blunt ends required for ligation of the vector. The modified vector was electroporated into electrocompetent ER2738 cells and then immediately placed in 1 mL of super optimal broth with catabolite repression medium (New England Biolabs) and grown for 45 min at 37°C. The resulting culture was then placed into 50 mL of a 1:100 diluted overnight culture and grown for 4.5 h. The amplified phage were purified using the protocol stated above and titered. Plaques were picked after 18 h and sequenced to verify the peptide being displayed on the phage surface.

**Fluorescent Labeling of Phage.** Phage particles were labeled using the Alexa Fluor 488 protein labeling kit (Invitrogen). The Alexa Fluor 488 contains a tetrafluorophenyl ester which reacts with the primary amine groups on the coat proteins of the phage.  $2 \times 10^{12}$  pfu in deionized (DI) water or PBS were added to DI water to obtain a total volume of 500  $\mu$ L. The phage solution was then added to 50  $\mu$ L of 1 M sodium bicarbonate and the resulting solution was placed into a vial containing the fluorescent dye and was at room temperature for 1 h. The phage were then purified with PEG/NaCl to remove the excess unreacted dye and titered. To resemble the phage screening experiments,  $2 \times 10^{11}$  pfu was added to the donor compartment of the FDC and the skin samples were harvested after 24 h for imaging.

**Macromolecule Penetration in Porcine Skin.** To conjugate the peptide to the macromolecule streptavidin, 80  $\mu$ L of a 1 mg/mL biotinylated peptide solution was incubated with 20  $\mu$ L of a 2 mg/mL streptavidin-Alexa Fluor 488 conjugate (Invitrogen) solution and incubated at room temperature for 30 min. The resulting solution was then placed into the donor compartment of the FDC. For the delivery of quantum dots into the skin, 198  $\mu$ L of a 100 ng/mL biotinylated peptide solution was incubated with 2  $\mu$ L of QDot 525 streptavidin conjugate (Invitrogen) for 1 h at room temperature. The 200  $\mu$ L suspension was then placed into the donor compartment of the FDC. All skin samples were harvested after 24 h.

**Preparation of Skin Samples for Confocal Microscopy Imaging.** The skin samples were placed into 4% paraformaldehyde (Electron Microscopy Sciences) overnight at 4°C immediately after being harvested and rinsed with DI water. Skin samples were then frozen in OCT compound and sectioned at a thickness of 20  $\mu$ m on a cyrotome (Leica). The tissues were mounted on slides which were positively charged to adhere the tissue to the glass slide (Fisher Scientific). The slides were washed in DI water for 5 min prior to staining with 5  $\mu$ g/mL Hoechst 33342 (Invitrogen) for 5 min. The slides were then washed again in DI water for 5 min and then allowed to dry completely at room temperature in the dark. Ten microliters of Permount mounting medium (Fisher Scientific) was placed on top of the skin section along with a glass cover slip and then the slides were sealed. All samples were imaged on a confocal microscope (Leica and Olympus Fluoview 500).

**Stratum Corneum (SC) Studies.** To isolate the SC from full thickness skin, the skin was placed in a 60°C water bath for 90 s. After removal from the water bath, the epidermis was separated from the dermis. The SC was then placed epidermis side down in a Petri dish containing 0.25% trypsin to remove the epidermis from

the SC. The SC was washed in DI water and then allowed to dry completely at room temperature. To delipidize the SC, the SC was placed in the following chloroform:methanol solvent mixtures: 2:1 (vol/vol), 1:1 (vol/vol), and 1:2 (vol/vol) for 15 min each. To confirm the removal of lipids, FTIR was performed on the SC samples before and after exposure to the solvent mixtures.

**FTIR Spectroscopy of SC.** FTIR was performed on SC samples to see the effects different peptide solutions had on the SC structure. SC was cut into  $1.5 \times 1.5$  cm pieces and a control spectrum was obtained for each piece prior to exposure with peptide. Two milliliters of a peptide solution was then incubated with the SC for 24 h. The SC samples were then rinsed with DI water and allowed to completely dry at room temperature. The spectra were read again for each SC sample and the before and after spectra were compared to determine the effect each peptide had on SC structure. Spectra were obtained using a Nicolet Magna 850 spectrometer with a resolution of  $2 \text{ cm}^{-1}$  and averaged over 400 scans.

**Cell Culturing Conditions.** Human adult epidermal keratinocytes (Invitrogen) were cultured in EpiLife Medium (Invitrogen) supplemented with Human Keratinocyte Growth Supplement (Invitrogen), human skin fibroblasts [American Type Culture Collection (ATCC)] were cultured in Dulbecco's modified Eagle's medium (ATCC) supplemented with 10% fetal bovine serum, pooled human umbilical vein endothelial cells (HUVEC, Lonza) were cultured in M199 medium on 1% gelatin-coated flasks supplemented with 15% fetal bovine serum,  $15 \mu\text{g/mL}$  endothelial cell growth supplement,  $100 \mu\text{g/mL}$  heparin, and  $2 \text{ mM}$  L-glutamine, and MDA-MB-231 breast cancer cells were cultured in Dulbecco's modified Eagle's medium (ATCC) supplemented with 10% fetal bovine serum. All cell culture media were supplemented with  $100 \text{ U/mL}$  penicillin and  $100 \mu\text{g/mL}$  streptomycin and cultures were grown under standard cell culture conditions ( $37^\circ\text{C}$  with  $5\% \text{ CO}_2$ ).

**Preparation of Cell Culture Samples for Confocal Microscopy Imaging.** After incubation, cells were washed with HBSS (Lonza) and incubated with 1% trypan blue for 5 min to quench any fluorescence on the surface of the cell. The cells were then fixed with 4% paraformaldehyde for 3 min and again washed in HBSS. The cells were then incubated with Hoechst 33342 ( $5 \mu\text{g/mL}$ ) for 5 min and then washed in HBSS. The cell culture dishes were then filled with HBSS and imaged using confocal microscopy (Olympus Fluoview 500).

**Endocytosis Inhibitors.** Endocytosis inhibitors were incubated with human keratinocytes prior to addition of fluorescently labeled control and SPACE peptide. The endocytosis inhibitors used were 5-(*N*-ethyl-*N*-isopropyl)amiloride (EIPA) (Invitrogen) and chlorpromazine, nystatin, and deoxy-D-glucose (Sigma). EIPA was dissolved in DMSO and used at a concentration of  $100 \mu\text{M}$ . Chlorpromazine, nystatin, and deoxy-D-glucose were dissolved in sterile water and used at the concentrations of  $10 \mu\text{g/mL}$ ,  $25 \mu\text{g/mL}$ , and  $5 \text{ mM}$ , respectively.

**Preparation of Samples for Flow Cytometry.** After incubation with fluorescently labeled peptide, the media was removed and cells were washed three times for 5 min each in HBSS to remove residual fluorescence. Trypsin (0.25%, HyClone) was used to remove the cells from the cell culture plate. The cells were then centrifuged at  $5,000 \text{ rpm}$  for 5 min to pellet the cells. The cell pellet was resuspended in PBS, pH 7.4 on ice and samples were analyzed using the FACSaria flow cytometer.

**Conjugation of Peptide to siRNA.** A  $10 \text{ mM}$  peptide solution was incubated with a  $10 \text{ mM}$  solution of *N*-(3-Dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDAC, Sigma) and a

$9.5 \text{ mM}$  solution of *N*-Hydroxysulfosuccinimide sodium salt (NHS, Sigma) in equal parts in MES buffer (pH 5.5) for 15 min. The amine modified siRNA was then added to the mixture to conjugate the peptide to siRNA and allowed to mix overnight.

**Mathematical Model.** Diffusion through intercellular lipids represents the classical mechanism for transdermal permeation of molecules. This mechanism, however, is generally limited to small, lipophilic molecules such as nicotine and fentanyl. Permeation of large, hydrophilic molecules is relatively less studied. Nonetheless, an increasing number of studies have reported and discussed transdermal permeation of hydrophilic macromolecules such as inulin ( $5 \text{ kDa}$ ) and dextran ( $70 \text{ kDa}$ ). Transdermal transport of such solutes is attributed to two pathways; (i) polar or porous pathways and (ii) appendages (follicles). Mathematical models have been developed to describe contributions of both pathways. Below, we extend these models to phage.

Basics of these models have already been published (1, 2) and a summary of these models is provided below. These models have been applied to describe transport of large molecules such as dextran, (hydrodynamic radius of  $2.6 \text{ nm}$ ), which though smaller than the radius of the phage ( $\sim 4 \text{ nm}$ ), is of the same order of magnitude. The following analysis is based on extrapolation of these models and provides informative context for interpreting phage permeation through skin.

**Polar pathway.** Polar (or porous) pathways have been used to describe transdermal diffusion of several hydrophilic solutes including macromolecules (1, 3–10). To cross the SC, hydrophilic solutes need to penetrate multiple lipid bilayers. However, given the low permeabilities of hydrophilic solutes across lipid bilayers, it appears unlikely that hydrophilic molecules can diffuse across the SC by the classical partition-diffusion process that plays an important role for hydrophobic solutes. Transdermal penetration of such solutes has been proposed to take place primarily through defects in the SC that exist in various physical forms including grain boundaries, fault-dislocations, nanoscale pinholes, or other abnormalities in skin structure. Hydration of the SC may further increase the occurrence of such defects. The precise size of these defects depends on the type of defect and may span a length scale of  $1\text{--}100 \text{ nm}$ .

A general expression for the permeability coefficient,  $K_p^{\text{pore}}$ , of a hydrophilic permeant diffusing through skin is given by the porous pathway as follows:

$$K_p^{\text{pore}} = \frac{\epsilon D^\infty}{\tau L} \left[ \int_0^\infty \gamma(r) H(\lambda) dr \right], \quad [\text{S1}]$$

where  $\epsilon$ ,  $\tau$ , and  $L$  are the porosity, tortuosity, and thickness of the membrane, respectively, and  $D^\infty$  is the solute diffusion coefficient in infinite dilution.  $H(\lambda)$  is the steric hindrance factor, where  $\lambda$  is the ratio of the hydrodynamic radius of the permeant,  $r_h$ , and the effective pore radius of the skin,  $r$  (that is,  $\lambda = r_h/r$ ). The relationship between  $H(\lambda)$  and  $\lambda$  is given by the hindered transport theory and is described in the literature (11). The pore size distribution,  $\gamma(r)$ , in skin has been described for porcine skin by the following function (4):

$$\gamma(r) = 0.024 \exp(-0.00045r^2). \quad [\text{S2}]$$

To put Eq. S2 in perspective, consider the energetics of pore (or void) formation in a medium, for example skin. The probability of pore formation can be related to the free energy of pore formation according to the following general equation:

$$\text{probability} \propto \exp\left(-\frac{\pi r^2 E}{kT}\right), \quad [\text{S3}]$$















**Fig. 55.** (A–C) Penetration of fluorescently labeled peptide into MDA-MB-231 human breast cancer cells after 6 h. Images of cells with no peptide (A), control peptide (B), and SPACE peptide (C). Scale bar: 50  $\mu\text{m}$ . (D–F) Confocal images of GFP-expressing endothelial cells after treatment with GFP siRNA complexed with Lipofectamine. (D) Treatment of cells with Lipofectamine only (no siRNA), (E) with Lipofectamine complexed with GFP siRNA, and (F) with Lipofectamine complexed with SPACE-GFP siRNA. Scale bar: 200  $\mu\text{m}$ .



**Fig. 56.** Penetration of fluorescently labeled peptide into mouse skin in vivo after 30 min. Three representative images are provided for each case. (A–C) Penetration of fluorescently labeled control peptide and (D–F) fluorescently labeled SPACE peptide. Scale bar: 50  $\mu\text{m}$ .

